Chartwatch - DXB, page-242

No probs @flotsam222,

I can see where you got the 80000 from (Investor presentation) and I have seen that quoted elsewhere as well, so all good. That report that was quoted I think you have to pay for, so couldn’t access it.

I used the number (40000) from a previous Retrophin article.

One thing for sure is that FSGS is becoming more common & diagnosis is by biopsy, so multiple studies I have read state that FSGS is likely to be underestimated in the USA & is disproportionate in African American & Asian patients. Approx 5400 patients are diagnosed each year in the USA & interestingly in Australia we have higher rates of FSGS diagnosed per population as our biopsy criteria is more liberal:

https://cjasn.asnjournals.org/content/12/3/502

Also, looking at numbers there may be some difference due to including a diagnosis of primary FSGS & secondary FSGS (viral, drug induced, other).

https://nephcure.org/livingwithkidneydisease/understanding-glomerular-disease/understanding-fsgs/

GLTAH